Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,708.62GBp
6:04am EDT
Change (% chg)

12.00p (+0.71%)
Prev Close
1,696.50p
Open
1,703.50p
Day's High
1,710.50p
Day's Low
1,693.00p
Volume
1,992,716
Avg. Vol
8,712,566
52-wk High
1,714.00p
52-wk Low
1,210.27p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals... (more)

Overall

Beta: 0.74
Market Cap(Mil.): £82,659.51
Shares Outstanding(Mil.): 4,872.35
Dividend: 19.00
Yield (%): --

Financials

  GSK.L Industry Sector
P/E (TTM): 135.33 36.73 37.52
EPS (TTM): 0.13 -- --
ROI: 1.83 15.28 14.48
ROE: 12.01 16.33 15.65

PRESS DIGEST- British Business - July 28

July 28 The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.

Jul 27 2016

BRIEF-Vectura initiates legal proceedings against GSK in the U.S.

* Vectura initiates legal proceedings against GlaxoSmithKline Plc (GSK)

Jul 27 2016

GlaxoSmithKline invests $360 million in UK despite Brexit

LONDON GlaxoSmithKline plans 275 million pounds ($361 million) of new investments at three drug manufacturing sites in Britain, signaling its confidence in the country despite last month's vote to leave the European Union.

Jul 27 2016

UPDATE 4-GlaxoSmithKline invests $360 mln in UK despite Brexit

* Weak pound could boost 2016 earnings by 19 percent (Adds Q2 earnings, further CEO and analyst comment, latest shares)

Jul 27 2016

BRIEF-GSK CEO: UK competitive post-Brexit but questions over drug regulation, science

* Ceo says board looking at internal and external candidates to be new ceo, decision around end year

Jul 27 2016

GSK outlook brightens as Brexit brings currency windfall

LONDON Demand for new medicines helped GlaxoSmithKline grow earnings in the second quarter and the drugmaker is set for big gains in the rest of 2016 thanks to a weak pound, after Britain's vote to leave the European Union.

Jul 27 2016

GSK outlook brightens as Brexit brings currency windfall

LONDON, July 27 Demand for new medicines helped GlaxoSmithKline grow earnings in the second quarter and the drugmaker is set for big gains in the rest of 2016 thanks to a weak pound, after Britain's vote to leave the European Union.

Jul 27 2016

GSK chases next biotech asthma drug with $230 million J&J deal

LONDON GlaxoSmithKline has bought global rights to an experimental drug from Johnson & Johnson for up to 175 million pounds ($230 million), raising its bet on a new generation of biotech medicines for severe asthma.

Jul 27 2016

GSK chases next biotech asthma drug with $230 mln J&J deal

LONDON, July 27 GlaxoSmithKline has bought global rights to an experimental drug from Johnson & Johnson for up to 175 million pounds ($230 million), raising its bet on a new generation of biotech medicines for severe asthma.

Jul 27 2016

GlaxoSmithKline invests $360 mln in post-Brexit UK manufacturing

LONDON, July 27 GlaxoSmithKline plans 275 million pounds ($361 million) of new investments at three drug manufacturing sites in Britain, signalling its confidence in the country despite last month's vote to leave the European Union. (Reporting by Ben Hirschler; Editing by David Holmes)

Jul 27 2016

Earnings vs. Estimates